Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 271

The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.

Smouldering multiple sclerosis: the ‘real MS’

Open access
Giovannoni, Gavin, Popescu, Veronica, Wuerfel, Jens, Hellwig, Kerstin, Iacobaeus, Ellen, Jensen, Michael B., García-Domínguez, José Manuel, Sousa, Livia, De Rossi, Nicola, Hupperts, Raymond, Fenu, Giuseppe, Bodini, Benedetta, Kuusisto, Hanna-Maija, Stankoff, Bruno, Lycke, Jan, Airas, Laura, Granziera, Cristina, Scalfari, Antonio·2022·Therapeutic Advances in Neurological Disorders

Abstract

Using a philosophical approach or deductive reasoning, we challenge the dominant clinico-radiological worldview that defines multiple sclerosis (MS) as a focal inflammatory disease of the central nervous system (CNS). We provide a range of evidence to argue that the ‘real MS’ is in fact driven primarily by a smouldering pathological disease process. In natural history studies and clinical trials, relapses and focal activity revealed by magnetic resonance imaging (MRI) in MS patients on placebo or on disease-modifying therapies (DMTs) were found to be poor predictors of long-term disease evolution and were dissociated from disability outcomes. In addition, the progressive accumulation of disability in MS can occur independently of relapse activity from early in the disease course. This scenario is underpinned by a more diffuse smouldering pathological process that may affect the entire CNS. Many putative pathological drivers of smouldering MS can be potentially modified by specific therapeutic strategies, an approach that may have major implications for the management of MS patients. We hypothesise that therapeutically targeting a state of ‘no evident inflammatory disease activity’ (NEIDA) cannot sufficiently prevent disability accumulation in MS, meaning that treatment should also focus on other brain and spinal cord pathological processes contributing to the slow loss of neurological function. This should also be complemented with a holistic approach to the management of other systemic disease processes that have been shown to worsen MS outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/17562864211066751

Cites

134 of 134 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 134 references

Cited by

See all 271

Metadata

Authors
Giovannoni, G., Popescu, V., Wuerfel, J., Hellwig, K., Iacobaeus, E., Jensen, M. B., García-Domínguez, J. M., Sousa, L., De Rossi, N., Hupperts, R., Fenu, G., Bodini, B., Kuusisto, H.-M., Stankoff, B., Lycke, J., Airas, L., Granziera, C., & Scalfari, A.
Venue
Therapeutic Advances in Neurological Disorders
Published
2022-01
Volume
15
Pages
17562864211066751-17562864211066751
ISSN
  • 1756-2856 (ISSN-L)
  • 1756-2864
OpenAlex
W4226087203
Cited by
271
References
134
FWCI
30.30
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Smouldering multiple sclerosis: the ‘real MS’. https://app.cochat.ai/papers/10.1177/17562864211066751
The paper
Giovannoni, G., Popescu, V., Wuerfel, J., Hellwig, K., Iacobaeus, E., Jensen, M. B., García-Domínguez, J. M., Sousa, L., De Rossi, N., Hupperts, R., Fenu, G., Bodini, B., Kuusisto, H.-M., Stankoff, B., Lycke, J., Airas, L., Granziera, C., & Scalfari, A. (2022). Smouldering multiple sclerosis: the ‘real MS’. Therapeutic Advances in Neurological Disorders. https://doi.org/10.1177/17562864211066751

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.